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Introduction: The combination of opioids and central nervous system depressants such 
as benzodiazepines and barbiturates has an additive effect on the frequency of oversedation 
and respiratory depression requiring naloxone use in hospitalized patients. Gabapentinoids 
(gabapentin and pregabalin) are frequently prescribed with opioids for their opioid-sparing and 
adjuvant analgesic effects. There is limited literature on the risk of respiratory depression due 
to the combination of opioids and gabapentinoids requiring naloxone administration.
Methods: This retrospective study evaluated patients who were prescribed opioids and at least 
one dose of naloxone between March 1, 2014 and September 30, 2016. The primary objec-
tive of this study was to compare the frequency of respiratory depression among patients who 
received naloxone and opioids (non-gabapentinoid group) with those who received naloxone, 
opioids, and gabapentinoids (gabapentinoid group). Secondary objectives included comparing 
the association of oversedation, using the Pasero Opioid-induced Sedation Scale, and various 
risk factors with those in the gabapentinoid group.
Results: A total of 153 patient episodes of naloxone administration (102 in the non-gabapen-
tinoid and 51 in the gabapentinoid groups) in 125 unique patients were included in the study. 
For the primary objective, there were 33 episodes of respiratory depression associated with the 
non-gabapentinoid group (33/102=32.4%) versus 17 episodes of respiratory depression with 
the gabapentinoid group (17/51=33.3%) (p=0.128). Secondary objectives showed a significant 
association between respiratory depression and surgery in the previous 24 hours (p=0.036) as 
well as respiratory depression and age >65 years (p=0.031) for patients in the non-gabapentinoid 
group compared to the gabapentinoid group.
Conclusion: There was no significant association of respiratory depression in the gabapen-
tinoid group versus the non-gabapentinoid group. There was an increased risk of respiratory 
depression in the gabapentinoid group, specifically in patients who had surgery within the 
previous 24 hours.
Keywords: naloxone, opioid analgesics, respiratory depression, gabapentin, pregabalin, POSS
Introduction
Opioid-related adverse events, specifically respiratory depression, that necessitate 
the use of naloxone occur frequently in hospitals worldwide. The Joint Commission 
reported that 11% of opioid-related adverse drug events were attributed to excessive 
dosage and medication interactions.1 The Joint Commission reported that the most 
commonly associated medication interactions leading to side effects were benzodiaz-
epines and cardiac medications. Additionally, the Joint Commission estimated that on 
average, the incidence of postoperative patients experiencing respiratory depression was 
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approximately 0.5%. This is due to inadequate monitoring, 
lack of knowledge regarding differing potencies of opioids, 
and improper prescribing.1
In one study, hospitalized patients with multiple risk fac-
tors were found to have a higher risk of receiving naloxone for 
respiratory depression and/or sedation compared to patients 
with fewer risk factors.2 Risk factors included patients receiv-
ing concomitant central nervous system (CNS) depressant 
medications, and those with history of smoking, renal disease, 
cardiac disease, and respiratory disease.2
A recent study at UC San Diego Health (UCSDH) 
evaluated naloxone use in hospitalized patients receiving 
opioids.3 Only 24% of the patients who received naloxone 
received the drug for the reversal of respiratory depression; 
the remaining patients received naloxone for oversedation as 
documented by the validated Pasero Opioid-induced Seda-
tion Scale (POSS).3–5 The study also showed that patients 
receiving naloxone for respiratory depression often received 
other CNS depressant medications (such as antiepileptic 
drugs [AEDs]) in addition to opioids. Of those who received 
AEDs, 70% of patients received gabapentin.3 The study also 
found that patients who received benzodiazepines and opioids 
were significantly more likely to have respiratory depression 
reversal than those who did not receive benzodiazepines. 
Interestingly, gabapentin coadministration with opioids did 
not significantly affect reversal of respiratory depression.3
Currently, gabapentin and pregabalin are US Food and 
Drug Administration-approved for postherpetic neuralgia 
in adults as well as adjunctive therapy in the treatment of 
partial-onset seizures.6,7 Gabapentinoids (gabapentin and 
pregabalin) are prescribed frequently in the hospital as well 
as in the outpatient setting for off-label indications such as 
acute and chronic pain, anxiety, sleep disorders, migraines, 
and drug and alcohol withdrawal.8–10 With the frequent use of 
gabapentinoids for various indications, there have been some 
studies examining the oversedating effect of gabapentinoids, 
including respiratory depression.11,12
Given the published literature supporting the increased 
frequency for various uses of gabapentinoids as well as 
their risk for sedation and possibly respiratory depression, 
we aimed to determine the additive effect of opioids and 
gabapentinoids on incidence of respiratory depression com-
pared to opioids alone. Naloxone administration was used 
as a marker of opioid-related respiratory depression. A chart 
review of all naloxone administrations was then performed 
to identify those cases that met our definition of respiratory 
depression. We hypothesized that in patients who received 
naloxone, the combination of opioids and gabapentinoids 
would lead to an increased risk of respiratory depression, 
compared to prescription of opioids alone.
Methods
The UCSDH Human Research Protections Program (HRPP) 
granted institutional review board approval. Patient consent 
to review their medical records was waived by the HRPP 
because the research was minimal risk, the waiver would 
not adversely affect patients, and the research could not have 
been practically conducted without the waiver. An adequate 
plan to protect the identifiers, including using deidentified 
data as much as possible and utilizing password protection, 
was detailed in research plan.
This was a retrospective study of hospitalized patients 
receiving naloxone and opioids (non-gabapentinoid group) 
compared to patients receiving naloxone, opioids, and gaba-
pentinoids (gabapentinoid group) between March 1, 2014 and 
September 30, 2016. Patients were excluded if they received 
naloxone in the intensive care unit, emergency department, 
or postacute care unit. Patients were also excluded if they 
were prisoners, <18 years of age, and if they had received 
a benzodiazepine within 24 hours of receiving naloxone.
Data collection
All data were collected from UCSDH EPIC™ (Boston Sci-
entific, Marlborough, MA, USA) electronic medical record 
(EMR) and recorded on a Microsoft Excel™ (Microsoft Corp., 
Redmond, WA, USA) spreadsheet. Patient demographic data 
such as patient name, medical record number, age, and sex 
were collected. Comorbid conditions such as surgery within 
the previous 24 hours, chronic heart failure (CHF), chronic 
obstructive pulmonary disease (COPD), and obstructive sleep 
apnea (OSA) were identified via past medical history docu-
mented in the patient’s chart via International Classification 
of Diseases, Ninth Revision codes at the time of encounter 
in which naloxone was administered. Kidney function was 
quantified by the patients’ glomerular filtration rates. Doses 
and times of naloxone administration, oxygen saturations 
documented immediately prior to and after naloxone admin-
istration, and respiratory rates immediately prior to and after 
naloxone administration were recorded from patient’s chart.
The primary objective of this study was to compare the 
association of naloxone administration with respiratory 
depression between the non-gabapentinoid group and the 
gabapentinoid group. Secondary objectives included the 
documented indication of naloxone in the UCSDH EPIC™ 
(ie, for sedation versus respiratory depression versus undocu-
mented/unknown); the association of sedation as measured 
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2637
Risk of respiratory depression with opioids
by POSS among non-gabapentinoid group and gabapentinoid 
group; the relationship between respiratory depression and 
age >65 years, comorbid conditions such as surgery within 
the previous 24 hours, CHF, COPD, OSA, and the patient’s 
glomerular filtration rate (GFR); as well as the dose of opioids 
in oral morphine equivalents and dose of gabapentinoids.
Respiratory depression was defined as a respiratory rate 
of <8 breaths per minute and oxygen saturation either below 
92% or a decrease of more than 5% from baseline in patients 
with a baseline of SPO
2
 <90%. Sedation level was measured 
by POSS. The POSS was recorded prior to the administra-
tion of naloxone as well as after administration. A POSS of 
1 or 2 is considered an acceptable level of awareness as the 
patient is either awake and alert or slightly drowsy but easily 
arousable. A POSS of 3 or 4 is considered excessively sedated 
and indicates a risk of respiratory depression. A POSS of 3 
indicates the patient is frequently drowsy, easily aroused but 
falls back asleep without constant stimulation, while a POSS 
of 4 indicates a patient is somnolent, with minimal or no 
response to verbal and physical stimulation. The distinction 
between respiratory depression and sedation was made based 
on physician documentation and nursing assessment records. 
If a patient did not meet criteria for respiratory depression as 
defined earlier or sedation was not identified in the physician 
and nursing documentation, the patient’s naloxone indication 
was classified as unknown.
The total daily dose of opioids in oral morphine equiva-
lents was calculated using the UCSDH equianalgesia conver-
sion chart (Figure S1). Total daily doses of gabapentinoids 
were classified as either high dose or low dose via an internal 
study definition. Patients were classified as high dose if they 
received ≥1,800 mg of gabapentin or ≥300 mg of pregabalin 
and low dose if they received <1,800 mg of gabapentin or 
<300 mg of pregabalin. Internal study definition of high ver-
sus low dose of gabapentinoids was determined using 50% 
of the maximum daily dose of gabapentin and pregabalin. 
Total doses of opioids and gabapentinoids were tabulated for 
the 24 hours prior to first dose of naloxone administered. An 
episode of naloxone administration was defined as a single 
dose or multiple doses given for respiratory depression or 
sedation with less than 2 hours between naloxone doses. If 
naloxone was administered ≥2 hours from a previous nalox-
one administration, this was defined as a separate episode.
Statistical analysis
Demographics and the primary objective were analyzed using 
χ2 and/or Fisher’s exact tests, with significance set at p<0.05. 
All analyses were conducted using IBM SPSS, version 24 
(Armonk, NY, USA).
Results
There were 125 unique patients who met the inclusion crite-
ria: 89 unique patients in the non-gabapentinoid group and 36 
unique patients in the gabapentinoid group (Table 1). A total 
of 153 episodes of naloxone administration occurred during 
the study period, with 102 episodes in the non-gabapentinoid 
group and 51 episodes in the gabapentinoid group.
For the primary objective, there were a total of 50 epi-
sodes of respiratory depression: 33 episodes of respiratory 
depression associated with the non-gabapentinoid group 
(33/102=32.4%) versus 17 episodes of respiratory depres-
sion with the gabapentinoid group (17/51=33.3%) (p=0.128, 
df=2) (Figure 1). When respiratory depression was compared 
in patients who had sedation and unknown documentation 
Table 1 Unique patient demographics and variables (n=125 unique patients)
Unique patient demographics (n=125) Non-gabapentinoids group (n=89) Gabapentinoids group (n=36) p-value
Age 0.031
≥65 years 49 (55%) 12 (33.3%)
Sex 0.076
Male 46 (51.7%) 12 (33.3%)
Comorbidities
Surgery in the last 24 hours 19 (21.3%) 2 (5.5%) 0.036
CHF 15 (16.5%) 8 (22.2%) 0.611
COPD 11 (12%) 5 (13.8%) 0.776
OSA 10 (11.2%) 2 (5.5%) 0.506
GFR 0.444
>60 mL/min 43 (48.3%) 20 (55.5%)
>30–60 mL/min 25 (28.1%) 6 (16.7%)
>10–30 mL/min 16 (18%) 9 (25%)
<10 mL/min 5 (5.6%) 1 (2.8%) 
Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; OSA, obstructive sleep apnea.
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 combined, there was also no significant difference between the 
non-gabapentinoid and gabapentinoid groups (p=1.00, df=1).
For the secondary objectives, in the non-gabepentinoid 
group naloxone was administered for sedation in 42% of 
episodes. In the gabapentinoids group, naloxone was admin-
istered for unknown reasons in 39% of episodes (Figure 1). 
In the non-gabapentinoid group, naloxone was given for a 
POSS of 3 or 4 (internally defined as sedation in our study) 
38.2% of the time versus 45.1% of the time in the gabapenti-
noid group (p=0.323, df=5) (Figure 2). Even when naloxone 
administration was compared for those having POSS scores 
of 0–2, 3–4, and not documented, there was no significant 
difference (p=0.471, df=2). In the non-gabapentinoid group, 
the majority of the patients were ≥65 years old (55%), 
whereas in the gabapentinoid group 33.3% of patients were 
≥65 years old (p=0.031). There were 51.7% male in the non-
gabapentinoid group and 33.3% male in the gabapentinoid 
group (p=0.076). The non-gabapentinoid group had signifi-
cantly more patients who had surgery in the last 24 hours 
(21.3%) versus the gabapentinoid group (5.5%) (p=0.036). 
Patients in the gabapentinoid group had similar numbers 
of patients with CHF (22.2%) and COPD (13.8%) as the 
non-gabapentinoid group (CHF [16.5%] and COPD [12%]; 
p=0.611, p=0.776, respectively). The number of patients in 
the non-gabapentinoid group that had a past medical history 
of OSA were comparable to those in the gabapentinoid group 
(11.2 versus 5.5%, respectively, p=0.506). In both groups, a 
majority of the patients had a GFR >60 mL/min, and about 
Figure 1 Indication of naloxone use based on the EMR.
Notes: *Pearson χ2 statistical analysis (p=0.128; n=153 episodes of naloxone administration; 17/51 episodes in gabapentinoid group and 33/102 episodes in non-gabapentinoid 
group for respiratory depression as defined in our study.
Abbreviation: EMR, electronic medical record.
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three-quarters of the patients had a GFR at least >30 mL/
min (Table 1).
The average morphine equivalent daily dose in the non-
gabapentinoid group was 63.9 mg (±70.5 standard deviation 
[SD]) versus 89.9 mg (±115 SD) in the gabapentinoid group. 
The majority of the patients in the gabapentinoid group were 
prescribed low doses of gabapentinoids (82.4%). In the 
non-gabapentinoid group, there were 57 episodes (55.8%) 
involving acute pain, 29 episodes (28.4%) involving chronic 
pain, and 16 episodes (15.8%) involving an undocumented 
indication for opioids, while in the gabapentinoid group, there 
were 31 episodes (60.7%) in which patients had received 
opioids for acute pain, 15 episodes (29.3%) involving opioids 
for chronic pain, and 5 episodes (10%) receiving opioids for 
an undocumented or unclear indication (p=0.436).
Discussion
Overall, among patients who received a combination of opi-
oids and gabapentinoids, respiratory depression did not occur 
more frequently when compared to opioids alone despite 
the fact that the gabapentinoid group received higher daily 
doses of opioids. Although there was no difference observed 
in the frequency of respiratory depression between the two 
groups, it was noted that the majority of the patients in the 
gabapentinoid group received low-dose gabapentinoid. In a 
previous small cohort study of nine patients, 44% of patients 
experienced respiratory depression and/or sedation with the 
combination of gabapentinoids and opioids with dosages of 
gabapentinoids administered as high as 3,600 mg/d.13 There-
fore, higher dosages of gabapentinoids when concomitantly 
used with opioids may place the patient at a higher risk of 
developing respiratory depression than the lower dosages of 
gabapentinoids that were seen in this study. Beyond the scope 
of this study, it is noted that there have been recent reports of 
recreational use of gabapentinoids concomitantly with opioids 
to further enhance drug users’ high experience. Therefore, fur-
ther studies would be beneficial to evaluate if higher dosages 
of gabapentinoids when combined with opioids also places 
these individuals at a higher risk of respiratory depression.
A Joint Commission report indicated that patients are 
at an increased risk of developing respiratory depression 
postoperatively.1 Commonly, gabapentinoids are used as 
perioperative and postoperative adjuvant analgesics to reduce 
opioid doses.15–17 With this common practice, one case series 
found that, postoperatively, respiratory depression occurred 
more frequently with the combination of opioids and 
 gabapentinoids if the patients were older, had OSA, or had 
poor renal function.16 In our study, the non-gabapentinoids 
group had significantly more patients with recent surgery 
than the gabapentinoids group. Additionally, the patients 
in the gabapentinoids group were younger, with seemingly 
fewer diagnoses of OSA and chronic kidney disease stage 
4 in comparison to those in the non-gabapentinoids group, 
although this was not statistically significant. The lower fre-
quency of these comorbid conditions in the gabapentinoid 
group may have contributed to fewer episodes of respiratory 
depression in comparison to the non-gabapentinoid group.
Respiratory depression has been shown to occur more 
frequently in patients who have received higher doses of 
opioids with or without the addition of other sedating medica-
tions, especially in the postoperative period.14 Interestingly, 
in our study, the non-gabapentinoid group had lower daily 
oral morphine equivalents then the gabapentinoid group. It is 
unclear why, but this may have been due to other comorbidities 
that were not accounted for in this study. Some confounding 
variables that could account for this phenomenon could be that 
the patients in the non-gabapentinoid group were more likely 
to be opioid naïve versus opioid tolerant and experienced 
respiratory depression at lower dosages of opioids. However, 
it would be anticipated that if patients were opioid naïve, they 
would be receiving opioids for acute pain; however, there was 
no greater association of patients in the non-gabapentinoid 
group receiving opioids for acute versus chronic pain.
This study found that there was no significant difference 
between respiratory depression and sedation among those 
who received gabapentinoids and those who did not. Addi-
tionally, there was a high percentage of naloxone administra-
tion for undocumented indications in both groups (25.5% in 
the non-gabapentinoid group and 39.1% in the gabapentinoid 
group). The inability to determine the indication for naloxone 
administration may have represented gaps in documenting 
respiratory depression or excessive sedation in the medical 
record. Lack of documentation may have skewed our data, 
providing an unclear depiction of the true respiratory depres-
sion risk associated with the gabapentinoid group.
Limitations
The main limitation of this study is the retrospective review 
which relied on the EMR for data. It was evident in this study 
that the EMR may not always have provided clear data on the 
respiratory and sedation status of patients prior to naloxone 
administration. These potential omissions in documentation 
may have impacted our results. Additionally, there may be 
some varying risk of opioid-related respiratory depression 
depending on the specific opioid and route of delivery. Given 
the sample size, it was not possible to provide granular  analysis 
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for different opioids and delivery routes. As a result, it is 
possible that differences between the two groups could have 
influenced the frequency of respiratory depression. Lastly, this 
study had a small sample size, which limits the generalizabil-
ity and does not permit the statistical analysis to be performed.
Conclusion
In this retrospective analysis, we showed that there was no 
greater association of respiratory depression with the con-
comitant use of opioids and gabapentinoids compared to 
opioids alone. Further prospective and larger studies are war-
ranted to evaluate the risk of respiratory depression among 
patients who receive opioids and gabapentinoids, especially 
in the postoperative setting.
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Supplementary material
Figure S1 UCSDH equianalgesic opioid dosing guidelines.
Notes: Text shown in bold, red, or all-capitals is for emphasis. **Indicates the text is a note. ----Indicates not applicable.
Abbreviations: CURES, Controlled Substance Utilization Review and Evaluation System; IV, intravenous; min, minute; PCA, patient-controlled analgesia; PO, per oral; PRN, 
as needed; q, every; Ref, reference; UCSD, UC San Diego; UCSDH, UC San Diego Health.
